Kidney transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity.
Adalimumab
/ administration & dosage
Adult
Aged
Female
Follow-Up Studies
Glomerular Filtration Rate
Glomerulonephritis, IGA
/ complications
Hospitalization
Humans
Immunosuppression Therapy
Inflammatory Bowel Diseases
/ complications
Infliximab
/ administration & dosage
Kidney Failure, Chronic
/ complications
Kidney Transplantation
/ adverse effects
Male
Middle Aged
Patient Readmission
Polycystic Kidney Diseases
/ complications
Retrospective Studies
Risk Factors
Treatment Outcome
inflammatory bowel disease
kidney transplantation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
21
11
2018
revised:
19
12
2018
accepted:
18
02
2019
pubmed:
23
2
2019
medline:
13
2
2020
entrez:
23
2
2019
Statut:
ppublish
Résumé
Inflammatory bowel diseases (IBD) is a systemic disorder with possible renal involvement, yet data regarding the outcome of kidney transplantation (KT) in those patients, and IBD course post KT, are scarce. In this retrospective analysis, we studied the outcome of 12 IBD kidney recipients (seven Crohn's disease, five ulcerative colitis; primary kidney disease was IgA nephropathy in five, polycystic disease in four), compared to two control groups: matched controls and a cohort of recipients with similar kidney disease. During a follow-up period of 60.1 (11.0-76.6) months (median, interquartile range), estimated 5-year survival was 80.8 vs. 96.8%, with and without IBD, respectively (P = 0.001). Risk of death with a functioning graft was higher with IBD (HR = 1.441, P = 0.048), and with increased age (HR = 1.109, P = 0.05). Late rehospitalization rate was higher in IBD [incidence rate ratio = 1.168, P = 0.030], as well as rate of hospitalization related to infection [1.42, P = 0.037]. All patients that were in remission before KT, remission was maintained. Patients that were transplanted with mild or moderate disease remained stable or improved with Infliximab or Adalimumab treatment. In conclusion, IBD is associated with an increased risk of mortality, hospitalization because of infection and late rehospitalization after KT. Clinical course of IBD is stable after KT.
Substances chimiques
Infliximab
B72HH48FLU
Adalimumab
FYS6T7F842
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
730-738Informations de copyright
© 2019 Steunstichting ESOT.